Asthma: A brief overview

American Journal of the Medical Sciences

Volumn 324, Issue 4, 2002, Pages 174-179

  Shepherd, Jinna M ^a   Duddleston, David N ^a   Hicks, G Swink ^a   Low, Annette K ^a   Russell, Lori D ^a   Brown, C Andrew ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Leukotriene modifiers

Indexed keywords

ANTIASTHMATIC AGENT; ARACHIDONIC ACID; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR AFFECTING AGENT; LEVALBUTEROL; METHYLPREDNISOLONE; METHYLXANTHINE DERIVATIVE; MONTELUKAST; NEDOCROMIL SODIUM; PIRBUTEROL; PREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TRIAMCINOLONE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

AIRWAY OBSTRUCTION; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CHRONIC INFLAMMATION; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; MORTALITY; PATHOGENESIS; PEAK EXPIRATORY FLOW; SPIROMETRY; THORAX RADIOGRAPHY; UNITED STATES;

EID: 0036788479     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200210000-00002     Document Type: Conference Paper

References (25)

1. National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. NIH Publication no. 97-4051. Bethesda (MD): United States Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. Available at: URL: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm
2. Data fact sheet: asthma statistics. Bethesda (MD): United States Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. Available at: URL: http://www.nhlbi.nih.gov/health/prof/lung/asthma/asthstat.pdf
3. United States Centers for Disease Control and Prevention. National Center for Health Statistics. Vital Health Stat 10 1996;(200):104.
4. Burney PG, Chinn S, Rona RJ. Has the prevalence of asthma increased in children? Evidence from the national study of health and growth 1973-1986. BMJ 1990;300:1306-10.
5. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the U.S. N Engl J Med 1992;326:862-6.
6. Beasley CRW, Pearce NE, Crane J. Epidemiology of asthma mortality. In: Giembycz MA, O'Connor BJ, editors. Asthma: epidemiology, anti-inflammatory therapy and future trends. New York: Springer-Verlag; 2000.
7. Sly RM, O'Donnell R. Stabilization of asthma mortality. Ann Allergy Asthma Immunol 1997;78:347-54.
8. Births and deaths: preliminary data for 1997. National Vital Statistics Report, Vol. 47, No. 4. Public Health Service publication no (PHS) 99-1120. Atlanta (GA): United States Centers for Disease Control and Prevention, National Center for Health Statistics; 1997. Available at: URL: http://www.cdc. gov/nchs/data/nvsr/nvsr47/nvs47_04.pdf
9. Grant JA. Bronchial asthma: update on the revised guidelines for diagnosis and management. Prim Care 1998;25: 849-67.
10. Spina D. Asthma mediators: current views. J Pharm Pharmacol 2000;52:125-45.
11. Lordan JL, Holgate ST. Recent developments in the pathogenesis and epidemiological trends of asthma. J R Coll Physicians Lond 1999;33:418-25.
12. Lillington GA, Faul JL. Differential diagnosis of asthma in adults. In: Gershwin ME, Albertson TE, editors. Bronchial asthma: principles of diagnosis and treatment. 4th ed. New Jersey: Humana Press; 2001. p. 137-53.
13. Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann Allergy Asthma Immunol 1999;82:296-305.
14. Alexander JA, Hunt LW, Patel AM. Prevalence, pathophysiology, and treatment of patients with asthma and gastroesophageal reflux disease. Mayo Clin Proc 2000;75:1055-63.
15. Lazarus SC. Inflammation, inflammatory mediators, and mediator antagonists in asthma. J Clin Pharmacol 1998;38: 577-82.
16. Busse WW. Inhaled corticosteroids-first-line preventive therapy in asthma: evidence from the current medical literature. J Allergy Clin Immunol 1998;102: S17-22.
17. Leff AR. Pharmacologic management of asthma. J Allergy Clin Immunol 1998;101:S397-99.
18. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997;111:27S-34S.
19. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220: 568-75.
20. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996;98:1-13.
21. Sampson AP, Diamant Z. Leukotriene modulators. In: Yeadon M, Diamant Z, editors. New and exploratory therapeutic agents for asthma. New York: Marcel Dekker, Inc.; 2000. p. 285-328.
22. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997;127:472-80.
23. Spector SL. Leukotriene inhibitors and antagonists in asthma. Ann Allergy Asthma Immunol 1995;75:463-73.
24. Babu KS, Salvi SS. Aspirin and asthma. Chest 2000;118: 1470-6.
25. Condemi JJ, Goldstein S, Kalberg C, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Ann Allergy Asthma Immunol 1999;82: 383-9.